Interferon alfa-2b (Intron A)

Biologic (subtype unspecified)

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Hepatitis B, Melanoma, Follicular Lymphoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
US
  • Hairy cell leukemia in adultsOutside this platform's coverage
  • Intralesional treatment of condylomata acuminata of the external genital and perianal areas in adultsOutside this platform's coverage
  • AIDS-related Kaposi's sarcoma in selected adultsOutside this platform's coverage
  • Chronic hepatitis C in adults with compensated liver disease
Product first approved 1986FDA label

Development in Chronic Hepatitis B stopped as a strategic decision by the sponsor. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (12)
Melanoma
NCT01274338 · National Cancer Institute (NCI)
2011-06-17 – 2027-02-02 · Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
What this study did
NCT00003641 · ECOG-ACRIN Cancer Research Group
1999-03-25 – 2026-05-26 · Melanoma (Skin)
What this study did
NCT00004196 · University of Alabama at Birmingham
1999-10 – 2007-11 · Melanoma (Skin)
What this study did
NCT00003444 · Eastern Cooperative Oncology Group
1999-03-29 – 2003-09 · Melanoma (Skin)
What this study did
Other / comorbidity
NCT00569127 · National Cancer Institute (NCI)
2007-12-01 – 2027-01-31 · Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
What this study did
NCT00686478 · University of Alberta
— · Burn, Hypertrophic Scar
What this study did
NCT00402428 · Human Genome Sciences Inc.
2006-12 – 2009-02 · Chronic Hepatitis C
What this study did
NCT00411385 · Human Genome Sciences Inc.
2007-02 – 2008-10 · Chronic Hepatitis C
What this study did
NCT00002556 · National Cancer Institute (NCI)
1994-07 – 2006-01 · Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
What this study did
NCT00125814 · French National Agency for Research on AIDS and Viral Hepatitis
2001-12 – 2005-01 · HIV Infections
What this study did
Phase 2/3 (3)
Melanoma
NCT03552549 · Merck Sharp & Dohme LLC
1998-08-05 – 2001-02-19 · Melanoma
What this study did
Other / comorbidity
NCT00624325 · Foundation for Liver Research
2007-07 – 2010-12 · Chronic Hepatitis C
What this study did
NCT03547154 · Merck Sharp & Dohme LLC
1998-10-22 – 2001-02-20 · Chronic Myelogenous Leukemia
What this study did
Phase 2 (20)
Melanoma
NCT00539591 · St. Jude Children's Research Hospital
2008-05-09 – 2031-05 · Malignant Melanoma
What this study did
NCT01708941 · National Cancer Institute (NCI)
2013-03-25 – 2026-05-26 · Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
What this study did
NCT04093323 · Roswell Park Cancer Institute
2024-11-13 – 2025-06-19 · HLA-A2 Positive Cells Present, Refractory Melanoma
What this study did
NCT01100528 · Case Comprehensive Cancer Center
2009-11-11 – 2017-12-14 · Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Recurrent Intraocular Melanoma
What this study did
NCT00963664 · NeoPlas Innovation
2009-12 – 2016-12 · Melanoma, Malignant Melanoma
What this study did
NCT00004104 · NYU Langone Health
1998-06 – 2000-07 · Melanoma (Skin)
What this study did
Other / comorbidity
NCT03899987 · Roswell Park Cancer Institute
2019-11-29 – 2027-04-30 · Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
What this study did
NCT03403634 · Roswell Park Cancer Institute
2018-04-19 – 2021-08-29 · Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
NCT00126594 · National Cancer Institute (NCI)
2005-06 – 2013-08 · Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
What this study did
NCT00919633 · Medtronic Corporate Technologies and New Ventures
2009-06 – 2012-07 · Hepatitis C
What this study did
NCT00471484 · National Cancer Centre, Singapore
started 2007-03 · Liver Cancer
What this study did
NCT01158534 · Case Comprehensive Cancer Center
2006-03 – 2010-10 · Renal Cell Cancer, Stage IV Renal Cell Cancer
What this study did
NCT00561912 · M.D. Anderson Cancer Center
2007-10 – 2009-11 · Renal Cell Carcinoma
What this study did
NCT00176527 · University of Medicine and Dentistry of New Jersey
2002-11 – 2007-08 · Prostate Cancer
What this study did
NCT00006384 · City of Hope Medical Center
2000-11 – 2007-02 · Kidney Cancer
What this study did
NCT00293527 · Ohio State University Comprehensive Cancer Center
est. completion 2006-11 · Renal Cancer
What this study did
NCT00101114 · National Cancer Institute (NCI)
2004-09 – 2006-05 · Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
What this study did
NCT00323505 · Royal Marsden NHS Foundation Trust
2001-03 – 2004-12 · Multiple Myeloma
What this study did
NCT00006039 · Memorial Sloan Kettering Cancer Center
1999-12 – 2001-03 · Lymphoma, Small Intestine Cancer
What this study did
NCT00001114 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2000-03 · Sarcoma, Kaposi, HIV Infections
What this study did
Phase 1/2 (5)
Other / comorbidity
NCT04379518 · Roswell Park Cancer Institute
2020-11-17 – 2023-03-15 · Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
What this study did
NCT02568241 · Peking University People's Hospital
2015-12 – 2020-12 · Leukemia
What this study did
NCT02151448 · David Bartlett
2014-07 – 2019-02-18 · Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
What this study did
NCT01639885 · Leiden University Medical Center
2011-08 – 2014-01 · Recurrent Ovarian Cancer
What this study did
NCT00059358 · National Institute of Allergy and Infectious Diseases (NIAID)
2001-09 – 2005-06 · HIV Infections, Hepatitis C
What this study did
Phase 1 (16)
Melanoma
NCT02339324 · Yana Najjar
2015-03-06 – 2019-11-02 · Melanoma
What this study did
NCT01943422 · John Kirkwood
2013-10 – 2016-12 · Melanoma
What this study did
NCT01409174 · M.D. Anderson Cancer Center
2013-02 – 2016-05 · Melanoma
What this study did
NCT01462773 · Ohio State University Comprehensive Cancer Center
2006-01 – 2013-04 · Melanoma
What this study did
NCT00498979 · Case Comprehensive Cancer Center
2007-05 – 2012-01 · Stage IV Melanoma
What this study did
NCT00398450 · University of California, San Diego
2006-02 – 2010-04 · Melanoma (Skin)
What this study did
NCT00217542 · National Cancer Institute (NCI)
2005-07 – 2008-07 · Recurrent Melanoma, Recurrent Renal Cell Cancer, Stage III Melanoma, Stage IV Melanoma, Stage IV Renal Cell Cancer
What this study did
Other / comorbidity
NCT03599453 · Roswell Park Cancer Institute
2019-01-09 – 2023-03-21 · Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative, Anatomic Stage IV Breast Cancer AJCC, Progesterone Receptor Negative
What this study did
NCT04081389 · Roswell Park Cancer Institute
2019-12-06 – 2023-02-27 · Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
What this study did
NCT00217373 · National Cancer Institute (NCI)
2005-06 – 2015-03 · Adult Solid Neoplasm
What this study did
NCT01217359 · University of North Carolina, Chapel Hill
2010-05 – 2012-08 · Hepatitis C
What this study did
NCT00311558 · The Cleveland Clinic
2005-10 – 2012-01 · Cancer
What this study did
NCT00701298 · National Cancer Institute (NCI)
2009-04 – 2010-10 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00001035 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 1996-09 · HIV Infections, Hepatitis C
What this study did
NCT00000694 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 1992-08 · Sarcoma, Kaposi, HIV Infections
What this study did
Phase 4 (4)
Chronic Hepatitis B
NCT02360592 · Tongji Hospital
2013-06 – 2017-04 · Hepatitis B, Chronic
What this study did
Other / comorbidity
NCT02323659 · Polish Lymphoma Research Group
2014-06-01 – 2018-03-31 · Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides
What this study did
NCT02199327 · Coordinación de Investigación en Salud, Mexico
2014-05 – 2017-07 · Conjunctival Intraepithelial Neoplasia, Corneal Intraepithelial Neoplasia
What this study did
NCT00854581 · University of Miami
2007-11 – 2011-11 · Lymphoma, Precancerous/Nonmalignant Condition
What this study did
Early phase / not applicable (3)
Melanoma
NCT01460875 · William Carson
2008-04-22 – 2014-01-05 · Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
What this study did
Other / comorbidity
NCT02185261 · Peking University People's Hospital
2014-06 – 2021-06 · Leukemia
What this study did
NCT00002270 · University of Miami
— · HIV Infections, Leukoencephalopathy, Progressive Multifocal
What this study did
Used as active comparator (7)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Melanoma
NCT02506153 · National Cancer Institute (NCI)
2015-11-10 – 2027-01-23 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma
What this study did
NCT00221702 · University Hospital, Bordeaux
2003-06 – 2010-10 · Melanoma, Neoplasm Metastasis
What this study did
Other / comorbidity
NCT01463592 · MTI Medical Private Limited, Pakistan
2010-06 – 2013-12 · Hepatitis C, Chronic
What this study did
Phase 2/3 (1)
Other / comorbidity
Phase 2 (2)
Melanoma
NCT00613509 · Sanofi Pasteur, a Sanofi Company
2008-06 – 2010-06 · Melanoma, Cancer
What this study did
Other / comorbidity
NCT01274273 · University of Aarhus
2009-10 – 2015-12 · Metastatic Renal Cell Carcinoma
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01121731 · Digna Biotech S.L.
2010-05 – 2013-01 · Chronic Hepatitis C Virus Infection, Genotype 1, Treatment-Experienced Patients, Relapses
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Hepatitis B: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Interferon Alfa-2b (Intron A): this drugApprovedBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
Entecavir (Baraclude)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Hepatitis B Immune Globulin (HepaGam B)ApprovedProtein / enzyme therapeuticHBsAgnot yet gradedNo reviewed efficacy summary in this indication
Interferon Beta-1b
Approved(overall)
Biologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Lamivudine (Epivir-HBV)
ApprovedUS marketing discontinued
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Peginterferon Alfa-2a (Pegasys)Approved—Type I interferon receptorPartial signalFeatured results are non-efficacy only in this race
Peginterferon Beta-1a (Plegridy)
Approved(overall)
Biologic (subtype unspecified)Type I interferon receptor, Interferon beta receptor (type I IFN signaling)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Rebif (interferon Beta 1a)
Approved(overall)
Biologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
Ropeginterferon Alfa-2b (Besremi)
Approved(overall)
Protein / enzyme therapeuticType I interferon receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Tenofovir Alafenamide (Vemlidy)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)Reliable signalFeatured results are non-efficacy only in this race
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Reliable signal
NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants
NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants
Besifovir Dipivoxil (Besivo)Phase 3Small moleculeHBV polymerase (reverse transcriptase)Partial signal
NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019).
Hepatitis B Immune Globulin (I.V.-Hepabig)Phase 3Polyclonal Antibody (human Hepatitis B Immunoglobulin)HBsAgnot yet gradedNo reviewed efficacy summary in this indication
Tenofovir Amibufenamide (Hengmu)Phase 3Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
TQA3605Phase 3—HBV core proteinnot yet gradedNo reviewed efficacy summary in this indication
TVAX-008Phase 3VaccineHepatitis B virus antigens (HBsAg + HBcAg)not yet gradedNo reviewed efficacy summary in this indication
AHB-171Phase 2RNA / oligonucleotideHBV RNAnot yet gradedNo reviewed efficacy summary in this indication
Daplusiran / TomligisiranPhase 2RNA / oligonucleotideHBV RNA (X and S transcripts)not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
HepalatidePhase 2PeptideNTCPnot yet gradedNo reviewed efficacy summary in this indication
Libevitug (HH-003)Phase 2Monoclonal antibodyHBV/HDV large envelope protein (PreS1 domain)not yet gradedNo reviewed efficacy summary in this indication
MetacavirPhase 2Small moleculeHBV reverse transcriptase (nucleoside analog)not yet gradedNo reviewed efficacy summary in this indication
REP 2139-MgPhase 2—HBsAg release (nucleic acid polymer)not yet gradedNo reviewed efficacy summary in this indication
T101Phase 2Biologic (subtype unspecified)HBV core, polymerase and envelope antigensnot yet gradedNo reviewed efficacy summary in this indication
TQA3810Phase 2—TLR8not yet gradedNo reviewed efficacy summary in this indication
CRMA-1001Phase 1/2Gene therapy / editingHBV genome (cccDNA and integrated DNA)not yet gradedNo reviewed efficacy summary in this indication
HepadvaxPhase 1/2VaccineHBsAg (PreS) immunizationnot yet gradedNo reviewed efficacy summary in this indication
Human Serum Albumin / Interferon Alpha2b Fusion ProteinPhase 1/2Biologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
LW231Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
PA1010Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
TQA3038Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
ACT201Phase 1RNA / oligonucleotideHBsAgnot yet gradedNo reviewed efficacy summary in this indication
CB06-036Phase 1—TLR8not yet gradedNo reviewed efficacy summary in this indication
DA-2803Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Entecavir (Cavir)
Phase 1(overall)
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
HECN30227Phase 1——not yet gradedNo reviewed efficacy summary in this indication
SA1211Phase 1RNA / oligonucleotideHepatitis B virus RNA (dual-target siRNA)not yet gradedNo reviewed efficacy summary in this indication
TVAX-028Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Interferon-Beta1
—(overall)
Biologic (subtype unspecified)Type I interferon receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Adefovir Dipivoxil (Hepsera)DiscontinuedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Obeticholic Acid (Ocaliva)Discontinued—FXRnot yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Telbivudine (Tyzeka)Discontinued—HBV polymerase (reverse transcriptase)Partial signal
NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Interferon alfa-2b (Intron A) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Phase 2Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-04-30 · NCT03899987 · CT.gov ↗
What to watch

See the full readout calendar ↗